Catheter Precision (NYSE: VTAK) extends related 8% note maturities

Rhea-AI Filing Summary

Catheter Precision, Inc. extended the maturities of several 8% Short Term Promissory Notes held by entities associated with its executive chair and CEO, David A. Jenkins. On December 31, 2025, the company entered into Second Amendments to these notes, moving their maturity dates from January 31, 2026 to January 31, 2028 for a $500,000 note held by Jenkins Family Charitable Institute and to January 31, 2029 for notes with principal amounts of $500,000, $150,000, $250,000 and $100,000 held by Mr. Jenkins and FatBoy Capital, L.P.

The filing highlights that Mr. Jenkins is the managing member of the general partner of FatBoy Capital and the settlor of the Jenkins Family Charitable Institute, and that he and his affiliates also hold stock options and rights to receive 11.77% royalties on net sales of the LockeT device. The amendments are treated as a material definitive agreement and a direct financial obligation for the company.

Insights

Credit and capital structure analyst

Catheter Precision pushed insider-held 8% notes from 2026 out to 2028–2029, easing near-term pressure but keeping related-party debt in place.

The company amended several 8% Short Term Promissory Notes on December 31, 2025, extending their maturities from January 31, 2026 to new dates in 2028 and 2029. Individual principal amounts include $500,000 payable to David A. Jenkins, three notes of $150,000, $250,000, and $100,000 payable to FatBoy Capital, L.P., and a $500,000 note payable to Jenkins Family Charitable Institute. This pushes out scheduled repayments without changing the disclosed coupon rate of 8%.

Because the noteholders are the CEO and entities linked to him, this remains a related-party funding source rather than third‑party refinancing. That can offer flexibility but also means a portion of the capital structure depends on terms negotiated with insiders. The filing also notes that Mr. Jenkins and his affiliates hold stock options and rights to receive 11.77% of net sales from the LockeT device, underscoring the extent of their economic ties to the business.

false 0001716621 0001716621 2025-12-31 2025-12-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

December 31, 2025

Catheter Precision, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38677		38-3661826
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1670 Highway 160 West

Suite 205

Fort Mill, SC 29708

(Address of principal executive offices, including zip code)

(973) 691-2000

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

______________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	VTAK	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2):

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

Second Amendment to Short Term Promissory Notes

On December 31, 2025, Catheter Precision, Inc. (the “Company”) amended each of its currently outstanding 8% Short Term Promissory Notes (the “Notes”) identified in the table below, each of which had a previously amended Maturity Date of January 31, 2026, to extend the maturity date as set forth in the table below.

The amendments were each memorialized by a Second Amendment to 8% Short Term Promissory Note(s) (the “Amendments”) entered into between the Company and the Holder of the relevant Note.

Original Issuance Date of Note	Holder	Principal Amount	Maturity Date
May 30, 2024	David A. Jenkins	$500,000	January 31, 2029
June 25, 2024	FatBoy Capital, L.P.	$150,000	January 31, 2029
July 1, 2024	FatBoy Capital, L.P.	$250,000	January 31, 2029
July 18, 2024	FatBoy Capital, L.P.	$100,000	January 31, 2029
July 25, 2024	Jenkins Family Charitable Institute	$500,000	January 31, 2028

David A. Jenkins is the Executive Chair and Chief Executive Officer of the Company; is the managing member of the general partner of FatBoy Capital, L.P.; and was the Settlor and Initial Trustee of Jenkins Family Charitable Institute (the “Trust”). The current Trustee of the Trust is Mr. Jenkins’ adult daughter. In addition to his roles as a director and officer of the Company, Mr. Jenkins and his affiliates own stock options issued by the Company and the rights to receive royalties on sales of our LockeT device equal to an aggregate 11.77% of net sales, as defined in the relevant agreements. Mr. Jenkins is a co-inventor of certain of our products and has previously assigned his rights in relation to those inventions to us. In addition, Missiaen Huck, Mr. Jenkins’ adult daughter, serves as our non-executive chief operating officer. For additional information see also Certain Relationships and Related Party Transactions in our proxy statement filed June 9, 2025.

Copies of the Amendments are filed as Exhibits 10.1 through 10.3 to this Form 8-K and are incorporated herein by reference.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The disclosure in Item 1.01 above regarding the Amendments is incorporated by reference into this Item 2.03.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
10.1		Second Amendment to 8% Short Term Promissory Notes Payable to FatBoy Capital, L.P.
10.2		Second Amendment to 8% Short Term Promissory Note Payable to David A. Jenkins
10.3		Second Amendment to 8% Short Term Promissory Note Payable to Jenkins Family Charitable Institute
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CATHETER PRECISION, INC.
Date: January 7, 2026	By:	/s/ Philip Anderson
		Philip Anderson
		Chief Financial Officer

3

FAQ

What did Catheter Precision (VTAK) change in its debt agreements?

Catheter Precision entered into Second Amendments to its 8% Short Term Promissory Notes on December 31, 2025, extending their maturity dates beyond the prior January 31, 2026 due date.

Which 8% notes had their maturity extended by Catheter Precision?

The amendments cover notes originally issued on May 30, 2024 to David A. Jenkins; on June 25, 2024, July 1, 2024, and July 18, 2024 to FatBoy Capital, L.P.; and on July 25, 2024 to Jenkins Family Charitable Institute.

What are the new maturity dates for Catheter Precision’s amended notes?

The amended 8% notes now mature on January 31, 2029 for the notes held by David A. Jenkins and FatBoy Capital, L.P., and on January 31, 2028 for the note held by Jenkins Family Charitable Institute.

How much principal is tied to each amended note at Catheter Precision?

Principal amounts include $500,000 payable to David A. Jenkins, $150,000, $250,000, and $100,000 payable to FatBoy Capital, L.P., and $500,000 payable to Jenkins Family Charitable Institute.

Why are these Catheter Precision notes considered related-party transactions?

David A. Jenkins is the company’s Executive Chair and CEO, manages the general partner of FatBoy Capital, L.P., and was the settlor and initial trustee of Jenkins Family Charitable Institute, linking all these noteholders to company insiders.

What other economic interests do David A. Jenkins and affiliates have in Catheter Precision?

The filing notes they hold stock options and rights to receive 11.77% of net sales of the LockeT device under royalty agreements, and Mr. Jenkins is a co‑inventor of certain products assigned to the company.